Furthermore, the incidence of neutropenia induced by second-generation ALK inhibitors like ceritinib, alectinib, and brigatinib or third-generation ALK inhibitors like lorlatinib is minimal. The gene discussed is ALK; the disease is Decreased total neutrophil count.